Skip to content

Effects of Inspiratory Muscle Training in Patients With Advanced Lung Disease

Effects of Inspiratory Muscle Training in Inspiratory Muscle Function, Functional Capacity, Quality of Life, Lung Function, Breathing Pattern and Thoracoabdominal Motion in Patients With Advanced Lung Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03511287
Acronym
IMTinALD
Enrollment
22
Registered
2018-04-27
Start date
2015-06-30
Completion date
2017-12-31
Last updated
2018-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Diseases, Pulmonary Disease

Keywords

inspiratory muscle training, advanced lung disease, maximal inspiratory pressure, inspiratory endurance

Brief summary

The aim of this clinical trial is to evaluate, the effects of inspiratory muscle training program in inspiratory muscle function, functional capacity, quality of life, lung function, breathing pattern and chest wall motion in patients with advanced lung disease. Patients were evaluated before the inspiratory muscle training, after 8 weeks of training and at follow-up which was performed 3 months after the end of the intervention.

Detailed description

Inspiratory Muscle Training (IMT) should be considered an additional intervention in the pulmonary rehabilitation program for patients with advanced lung disease. The aim of this study is to evaluate, the effects of inspiratory muscle training program in inspiratory muscle function, functional capacity, quality of life, lung function, breathing pattern and chest wall motion in patients with advanced lung disease. It is a quasi-experimental study with longitudinal design. Patients with advanced lung disease from the advanced lung disease and pre lung transplantation ambulatory performed home-based high intensity interval IMT for 8 weeks (two sessions per day, daily). In each session patients executed two times 30 breaths with one-minute rest between them. Resistance was set to the highest tolerable according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher. An experienced physiotherapist was responsible for weekly adjustments on the resistance of training as well as new assessment of maximal inspiratory pressure. Patients were evaluated before the inspiratory muscle training, after 8 weeks of training and at follow-up which was performed 3 months after the end of the intervention. Patients were evaluated by the same experienced researcher in all three moments of the study. Evaluations were performed in the Laboratory of research and evaluation of cardiorespiratory performance of Federal University of Minas Gerais.

Interventions

OTHERInspiratory Muscle Training

Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).

Sponsors

Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
Fundação de Amparo à Pesquisa do estado de Minas Gerais
CollaboratorOTHER
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
CollaboratorOTHER_GOV
Federal University of Minas Gerais
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All patients from the advanced lung disease and pre lung transplantation ambulatory

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* presence of inspiratory muscle weakness (Maximal Inspiratory Pressure - MIP ≤ 60 cmH2O or below the reference values proposed for the Brazilian population. * completion of a 36 sessions of PR or nonattendance in any pulmonary rehabilitation by the time of inclusion and no perspective of initiating it in the next 8 weeks. * absence of pre-existing neuromuscular, infectious, metabolic, psychiatric diseases or orthopedic problems that prevent from activities of daily living.

Exclusion criteria

* presented inspiratory muscle strength higher than 60 cmH2O or predicted value * unable to follow commands related to the measurements or to the IMT

Design outcomes

Primary

MeasureTime frameDescription
Change in Inspiratory muscle strengthBefore intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Maximal inspiratory pressure in cmH2O
Change in Inspiratory Muscle EnduranceBefore intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Inspiratory endurance time in seconds

Secondary

MeasureTime frameDescription
Change in chest wall motionBefore intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Optoelectronic plethysmography (lung volumes in liters)
Change in Functional Capacity (direct measure)Before intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Six minutes walking distance (meters)
Change in Lung FunctionBefore intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Spirometry
Quality of lifeBefore intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Saint George Respiratory questionnaire (total score) It is a 50 questions questionnaire. Total score can go from 0 to 100. Higher scores indicate worse quality of life.
Change in Functional Capacity (inderect measure)Before intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)London chest activity of daily living scale (total score) - It evaluates the dyspnea in daily activities. Consists in a 15 questions questionnaire with scores from 0-5 in each question. Total score varies from 0 to 75, the higher the score the major the limitation on daily activities due to dyspnea.
Change in Breathing patternBefore intervention, after 8 weeks intervention and follow-up (3 months after the end of intervention)Optoelectronic plethysmography (percentage of contribution of the 3 lung compartments to ventilation)

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026